Steadybase.

Telix Pharmaceuticals Ltd.

Website LinkedIn
  • TLX ยท Nasdaq
  • Pharmaceutical Preparations
  • North Melbourne, C3
  • CIK 0002007191

Updated from SEC filings through

Top things to know

Executives

Telix Pharmaceuticals Ltd is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in North Melbourne, C3. It trades as TLX on Nasdaq. Revenue was $804M in the fiscal year ending December 31, 2025, +55.6% from the year before.

Five-year financials

MetricFY2025FY2024FY2023
Revenue $804M
20-F, 2026-02-20
$517M
20-F, 2026-02-20
$333M
20-F, 2026-02-20
Operating income $29.8M
20-F, 2026-02-20
$55.2M
20-F, 2026-02-20
$11.0M
20-F, 2026-02-20
SG&A Not on file Not on file Not on file
Net income -$7.1M
20-F, 2026-02-20
$33.7M
20-F, 2026-02-20
$4.2M
20-F, 2026-02-20

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Christian Behrenbruch Christian Behrenbruch MD & Group CEO Form 4, May 6, 2026
Darren Charlton Smith Darren Charlton Smith Group Chief Financial Officer Form 4, September 14, 2026
Darren Joel Patti Group Chief Operating Officer Form 3, April 1, 2026
David Norman Cade Group Chief Medical Officer Form 3, April 1, 2026

What Telix Pharmaceuticals Ltd does

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease. Page 4 29 Telix ASX disclosure September 1, 2026.

Press release "About" paragraph, 10-K for the year ending October 20, 2026

Shares and governance

Shares outstanding 338.8 million (as of December 31, 2025) 20-F/A, March 20, 2026
Auditor PricewaterhouseCoopers (Melbourne, Australia) Latest 10-K

Insider trades

Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.

DateInsiderTradeSharesValueSource
September 7, 2026 Darren Charlton Smith
Group Chief Financial Officer
Buy 2,071 $20K Form 4, September 14, 2026
April 29, 2026 Christian Behrenbruch
MD & Group CEO
Buy 67,935 $997K Form 4, May 6, 2026

Recent 8-K events

No 8-K filings on file.

Frequently asked questions about Telix Pharmaceuticals Ltd

What does Telix Pharmaceuticals Ltd do?
In its own words, from Item 1 of its 10-K: "Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease. Page 4 29 Telix ASX disclosure September 1, 2026."
What is Telix Pharmaceuticals Ltd's revenue?
$804M for the fiscal year ending December 31, 2025, from its 20-F filed February 20, 2026.
Is Telix Pharmaceuticals Ltd profitable?
Telix Pharmaceuticals Ltd reported net income of -$7.1M for the fiscal year ending December 31, 2025.
Who is the CFO of Telix Pharmaceuticals Ltd?
Darren Charlton Smith, Group Chief Financial Officer, as named in a 4 filed September 14, 2026.
Where is Telix Pharmaceuticals Ltd headquartered?
North Melbourne, C3.
What is Telix Pharmaceuticals Ltd's stock ticker?
TLX, TLPPF on Nasdaq.
What industry is Telix Pharmaceuticals Ltd in?
Pharmaceutical Preparations, SIC code 2834.
What is Telix Pharmaceuticals Ltd's website?
telixpharma.com.
Is Telix Pharmaceuticals Ltd a public company?
Yes. Telix Pharmaceuticals Ltd files with the SEC under CIK 0002007191 and trades as TLX.
Who audits Telix Pharmaceuticals Ltd?
PricewaterhouseCoopers, Melbourne, Australia, as named in its latest annual report (10-K).
How many shares of Telix Pharmaceuticals Ltd are outstanding?
338.8 million shares as of December 31, 2025, from its 20-F/A filed March 20, 2026.
Have Telix Pharmaceuticals Ltd insiders traded stock recently?
Since April 29, 2026, officers and directors reported 0 open-market sales and 2 purchases worth about $1.0M on Forms 4 and 5. The most recent: Darren Charlton Smith (Group Chief Financial Officer) bought 2,071 shares on September 7, 2026.